Jeffrey Tong is a partner with Third Rock Ventures. He has over 20 years in building and growing early-stage biotechnology companies. Prior to joining Third Rock, Dr. Tong was Executive Chairman of the board of Delinia (acquired by Celgene), was President and CEO of Nora Therapeutics, and VP of Corporate and Product Development at Infinity Pharmaceuticals. Over the course of his career, he has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through Phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Earlier in his career, Dr. Tong worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research. In addition to Septerna, he currently serves on the boards of Rapport Therapeutics and numerous privately held biotechnology companies.
Dr. Tong received his AB in Biochemical Sciences from Harvard University, his AM and PhD in Chemistry from Harvard Graduate School of Arts and Sciences and his MMS from Harvard Medical School.